Alexza Pharmaceuticals

Alexza Pharmaceuticals, located in Mountain View, CA, is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's products are based on the Staccato system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner. ADASUVE is the first and only inhalation therapy for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. ADASUVE combines Alexza’s proprietary Staccato system with loxapine, an antipsychotic medicinal product. The Staccato system is a hand-held inhaler that delivers a drug aerosol to the deep lung that results in intravenous-like pharmacokinetics and rapid systemic effects. Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., is Alexza's commercial partner for ADASUVE in the United States. Grupo Ferrer Internacional SA is Alexza's commercial partner for ADASUVE in Europe, Latin America and the Commonwealth of Independent States countries. ADASUVE® and Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.
Company Growth (employees)
Mountain View, US
Size (employees)
27 (est)
Alexza Pharmaceuticals is headquartered in Mountain View, US

Key People at Alexza Pharmaceuticals

Leighton Read

Leighton Read

Darl Moreland

Darl Moreland

Vice President, Quality

Alexza Pharmaceuticals Office Locations

Alexza Pharmaceuticals has an office in Mountain View
Mountain View, US (HQ)
2091 Stierlin Ct

Alexza Pharmaceuticals Metrics

Alexza Pharmaceuticals Financial Metrics

Alexza Pharmaceuticals's revenue was reported to be $5 m in FY, 2015 which is a 10% decrease from the previous period.

Revenue (FY, 2015)

$5 m

Revenue growth (FY, 2014 - FY, 2015), %


Gross profit (FY, 2015)

($16.1 m)

Gross profit margin (FY, 2015), %


Net income (FY, 2015)

($21.3 m)

EBIT (FY, 2015)

($40 m)

Cash (31-Dec-2015)

$7.8 m
FY, 2013FY, 2014FY, 2015


$47.8 m$5.6 m$5 m

Revenue growth, %


Cost of goods sold

$11.2 m$15.9 m$21.1 m

Gross profit

$36.6 m($10.4 m)($16.1 m)

Gross profit Margin, %


Operating expense total

$34.9 m$27.1 m$45.1 m


$1.8 m($37.5 m)($40 m)

EBIT margin, %


Interest expense

$1.5 m$7.4 m$8.4 m

Net Income

($39.6 m)($36.7 m)($21.3 m)
FY, 2013FY, 2014FY, 2015


$17.3 m$15.2 m$7.8 m

Accounts Receivable


$1.5 m$3.1 m$3.2 m

Current Assets

$30.9 m$41.8 m$11 m


$15 m$14 m$3.3 m

Total Assets

$47.1 m$61.6 m$14.7 m

Accounts Payable

$3.8 m$1.8 m$442 k

Current Liabilities

$14.9 m$11.5 m$58.2 m

Additional Paid-in Capital

$350.3 m$359.3 m$360.6 m

Retained Earnings

($374.2 m)($411 m)($432.3 m)

Total Equity

($51.7 m)

Financial Leverage

-1.2 x
FY, 2013FY, 2014FY, 2015

Net Income

($39.6 m)($36.7 m)($21.3 m)

Depreciation and Amortization

$3.3 m$3.4 m$3 m

Accounts Receivable


($601 k)($822 k)($1.2 m)

Accounts Payable

$1.6 m($2 m)($1.4 m)

Cash From Operating Activities

($612 k)($41.5 m)($31.9 m)

Purchases of PP&E

($1.8 m)($2.4 m)($58 k)

Cash From Investing Activities

($10.3 m)($13.5 m)$19.5 m

Cash From Financing Activities

$10.5 m$52.9 m$5 m

Interest Paid

$863 k$4.2 m$2.8 m
Y, 2015


$50.5 k

Alexza Pharmaceuticals News

Alexza Pharmaceuticals Company Life

You may also be interested in